Year: 2025

Very Strong Third Quarter and Year-to-Date Performance Across the Business Net Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q’24 Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q’24 FY’25 Guidance Raised Above High End for All Key Operating and Financial MetricsARLINGTON, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter ended September 30, 2025. Third Quarter Performance    For the Three Months Ended September 30,    ($ in millions, except per share amounts)     2025     2024   Change (%) fTotal revenue   $ 580.4   $ 437.9   32.5 %Gross profit   $ 122.6   $ 99.9   22.7 %Operating income   $ 14.4   $ 5.8   147.8 %Net income a   $ 6.9   $ 3.5   94.1 %Non-GAAP adjusted net income b d e   $ 37.3   $ 25.1   49.1 %Net...

Millicom (Tigo) Q3 2025 Earnings Release Luxembourg, November 6, 2025 – Millicom is pleased to announce its third quarter 2025 results. Please find below links to the Q3 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q3 2025 Highlights*Revenue $1.42 billionOperating profit $390 million, and record Adjusted EBITDA $695 millionNet profit attributable to company owners $195 million, including approximately $138 million net profit from the closure of infrastructure transactionsEquity free cash flow $243 millionAdditional interim dividend declared in August of $2.5 per share, amounting approximately $420 million Leverage of 2.09x, benefiting from one-time cash proceeds of $537 million from infrastructure transactions Financial highlights ($ millions) Q3 2025 Q3 2024 ...

TEJON RANCH, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three and nine-months ended September 30, 2025. Third Quarter 2025 Financial and Operating HighlightsGAAP net income attributable to common stockholders for the third quarter of 2025 was $1.7 million, or net income per share attributable to common stockholders, basic and diluted, of $0.06. In the third quarter of 2024, the Company reported net loss attributable to common stockholders of $1.8 million, or net loss per share attributable to common stockholders, basic and diluted, of $0.07. This represents a positive change of $3.5 million in net income and an improvement of $0.13 per share compared to the same quarter last year. Revenues...

Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organicallyThird-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organicallyOctober divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 millionRaising full-year 2025 adjusted EBITDA and adjusted EPS guidanceDallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) — Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Third Quarter 2025 Financial Results Enovis’ third-quarter net sales of $549 million grew...

Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.  COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%. Ester Baiget, President & CEO:  “I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and in emerging and developed markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quarter, we indicate mid-single-digit organic sales growth...

Q3 2025 Both Revenues and EPS Significantly Exceeded Guidance Range, GM In-Line with Guidance Issued on August 7, 2025Company Q4 2025 Guidance: Revenues to be Flat QoQ, Gross Margin is Expected to be Flat to Slightly Up. Profit per Diluted ADS to be 2.0 Cents to 4.0 CentsQ3 2025 revenues were $199.2 million, a sequential decline of 7.3%, which significantly outperformed guidance range of a 12.0% to 17.0% decline Q3 GM reached 30.2%, in line with guidance of around 30% Q3 2025 after-tax profit was $1.1 million, or 0.6 cents per diluted ADS, substantially exceeding the guidance range of a loss of 2.0 to 4.0 cents Himax Q4 2025 revenues to be flat QoQ. GM to be flat to slightly up. Profit per diluted ADS to be in the range of 2.0 cents to 4.0 cents Himax remains optimistic about the Company’s automotive business outlook for the next few...